Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes

(2010) Nikolaus Marx et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy

(2010) F. Bardazzi et al.   Dermatologic Therapy

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

(2010) I. Hadjiyanni et al.   DIABETOLOGIA

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

(2010) Batya B. Davidovici et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation

(2010) Samuel Bremmer et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin

(2009) Pit Sertznig et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis

(2009) Rajan Mittal et al.   ARCHIVES OF DERMATOLOGY

Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice

(2007) Irene Hadjiyanni et al.   ENDOCRINOLOGY